• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

去整合素和金属蛋白酶9(ADAM9)的过表达与口腔鳞状细胞癌患者的不良预后相关。

Overexpression of a disintegrin and metalloproteinase 9 (ADAM9) in relation to poor prognosis of patients with oral squamous cell carcinoma.

作者信息

Wu Shuangjiang, Cheng Lang, Luo Tao, Makeudom Anupong, Wang Lei, Krisanaprakornkit Suttichai

机构信息

Department of Oral and Maxillofacial Surgery, The Affiliated Hospital, Southwest Medical University, Luzhou, China.

Department of Oral and Maxillofacial Surgery, The Affiliated Stomatological Hospital, Southwest Medical University, Luzhou, China.

出版信息

Discov Oncol. 2024 Oct 23;15(1):582. doi: 10.1007/s12672-024-01422-1.

DOI:10.1007/s12672-024-01422-1
PMID:39441449
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11499557/
Abstract

This study investigates the expressions of ADAM9, CDCP1 and t-PA in OSCC and their impacts on patient prognosis. Previous research has demonstrated the overexpression of ADAM9 and activation of plasminogen activator in OSCC, but CDCP1's role remains unexplored. While these biomolecules are known to contribute to lung cancer metastasis, their concurrent expressions in OSCC have not been thoroughly examined. Our aim is to assess the expressions of ADAM9, CDCP1, and t-PA in OSCC specimens, compare them with normal oral tissues, and explore their correlation with OSCC's clinicopathological features and patient survival outcomes.

摘要

本研究调查了ADAM9、CDCP1和t-PA在口腔鳞状细胞癌(OSCC)中的表达及其对患者预后的影响。先前的研究已证明ADAM9在OSCC中过表达以及纤溶酶原激活剂的激活,但CDCP1的作用仍未得到探索。虽然已知这些生物分子有助于肺癌转移,但它们在OSCC中的同时表达尚未得到充分研究。我们的目的是评估ADAM9、CDCP1和t-PA在OSCC标本中的表达,将它们与正常口腔组织进行比较,并探讨它们与OSCC临床病理特征和患者生存结果的相关性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/324d/11499557/6976c4459490/12672_2024_1422_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/324d/11499557/8847eaccc6ba/12672_2024_1422_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/324d/11499557/6976c4459490/12672_2024_1422_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/324d/11499557/8847eaccc6ba/12672_2024_1422_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/324d/11499557/6976c4459490/12672_2024_1422_Fig2_HTML.jpg

相似文献

1
Overexpression of a disintegrin and metalloproteinase 9 (ADAM9) in relation to poor prognosis of patients with oral squamous cell carcinoma.去整合素和金属蛋白酶9(ADAM9)的过表达与口腔鳞状细胞癌患者的不良预后相关。
Discov Oncol. 2024 Oct 23;15(1):582. doi: 10.1007/s12672-024-01422-1.
2
Overexpression of ADAM9 in oral squamous cell carcinoma.ADAM9在口腔鳞状细胞癌中的过表达。
Oncol Lett. 2018 Jan;15(1):495-502. doi: 10.3892/ol.2017.7284. Epub 2017 Oct 30.
3
ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis.ADAM9通过激活EGFR信号通路抑制miR-1,从而增强CDCP1,促进肺癌转移。
Oncotarget. 2017 Jul 18;8(29):47365-47378. doi: 10.18632/oncotarget.17648.
4
Involvement of the A disintegrin and metalloproteinase 9 in oral cancer cell invasion.ADAM9 在口腔癌细胞侵袭中的作用。
Eur J Oral Sci. 2021 Jun;129(3):e12775. doi: 10.1111/eos.12775. Epub 2021 Mar 30.
5
MiR-126 inhibits cell migration and invasion by targeting ADAM9 in oral squamous cell carcinoma.miR-126 通过靶向作用于 ADAM9 抑制口腔鳞状细胞癌的迁移和侵袭。
Eur Rev Med Pharmacol Sci. 2019 Dec;23(23):10324-10331. doi: 10.26355/eurrev_201912_19670.
6
High expression of a disintegrin and metalloproteinase-9 predicts a shortened survival time in completely resected stage I non-small cell lung cancer.解整合素金属蛋白酶-9的高表达预示着完全切除的Ⅰ期非小细胞肺癌患者生存时间缩短。
Oncol Lett. 2013 May;5(5):1461-1466. doi: 10.3892/ol.2013.1209. Epub 2013 Feb 22.
7
Expression of ADAM9 in CIN3 lesions and squamous cell carcinomas of the cervix.ADAM9在宫颈上皮内瘤变3级病变及宫颈鳞状细胞癌中的表达。
Gynecol Oncol. 2009 Aug;114(2):332-6. doi: 10.1016/j.ygyno.2009.05.005. Epub 2009 May 27.
8
ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway.ADAM9 通过纤溶酶原激活物途径促进肺癌向脑部转移。
Cancer Res. 2014 Sep 15;74(18):5229-43. doi: 10.1158/0008-5472.CAN-13-2995. Epub 2014 Jul 24.
9
Decreased Cytoplasmic Expression of ADAMTS14 Is Correlated with Reduced Survival Rates in Oral Squamous Cell Carcinoma Patients.ADAMTS14细胞质表达降低与口腔鳞状细胞癌患者生存率降低相关。
Diagnostics (Basel). 2020 Feb 23;10(2):122. doi: 10.3390/diagnostics10020122.
10
Pathogenesis and prognosis of primary oral squamous cell carcinoma based on microRNAs target genes: a systems biology approach.基于微小RNA靶基因的原发性口腔鳞状细胞癌的发病机制与预后:一种系统生物学方法
Genomics Inform. 2022 Sep;20(3):e27. doi: 10.5808/gi.22038. Epub 2022 Sep 30.

本文引用的文献

1
Identification of therapeutically potential targets and their ligands for the treatment of OSCC.鉴定用于治疗口腔鳞状细胞癌的具有治疗潜力的靶点及其配体。
Front Oncol. 2022 Sep 20;12:910494. doi: 10.3389/fonc.2022.910494. eCollection 2022.
2
Involvement of the A disintegrin and metalloproteinase 9 in oral cancer cell invasion.ADAM9 在口腔癌细胞侵袭中的作用。
Eur J Oral Sci. 2021 Jun;129(3):e12775. doi: 10.1111/eos.12775. Epub 2021 Mar 30.
3
miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.
miR-126-3p 的下调通过上调 ADAM9 和 VEGF-A 促进黑色素瘤对 dabrafenib 的获得性耐药。
J Exp Clin Cancer Res. 2019 Jun 21;38(1):272. doi: 10.1186/s13046-019-1238-4.
4
Salivary protease spectrum biomarkers of oral cancer.唾液蛋白酶谱生物标志物与口腔癌。
Int J Oral Sci. 2019 Jan 3;11(1):7. doi: 10.1038/s41368-018-0032-z.
5
Molecular targeted therapy: Treating cancer with specificity.分子靶向治疗:特异性治疗癌症。
Eur J Pharmacol. 2018 Sep 5;834:188-196. doi: 10.1016/j.ejphar.2018.07.034. Epub 2018 Jul 20.
6
MiR-129-5p functions as a tumor suppressor in gastric cancer progression through targeting ADAM9.miR-129-5p 通过靶向 ADAM9 在胃癌进展中发挥肿瘤抑制作用。
Biomed Pharmacother. 2018 Sep;105:420-427. doi: 10.1016/j.biopha.2018.05.105. Epub 2018 Jun 4.
7
Overexpression of ADAM9 in oral squamous cell carcinoma.ADAM9在口腔鳞状细胞癌中的过表达。
Oncol Lett. 2018 Jan;15(1):495-502. doi: 10.3892/ol.2017.7284. Epub 2017 Oct 30.
8
ADAM9 expression promotes an aggressive lung adenocarcinoma phenotype.ADAM9的表达促进了侵袭性肺腺癌表型。
Tumour Biol. 2017 Jul;39(7):1010428317716077. doi: 10.1177/1010428317716077.
9
ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis.ADAM9通过激活EGFR信号通路抑制miR-1,从而增强CDCP1,促进肺癌转移。
Oncotarget. 2017 Jul 18;8(29):47365-47378. doi: 10.18632/oncotarget.17648.
10
ADAM9 functions as a promoter of gastric cancer growth which is negatively and post-transcriptionally regulated by miR-126.ADAM9作为胃癌生长的促进因子,其受到miR - 126的负向转录后调控。
Oncol Rep. 2017 Apr;37(4):2033-2040. doi: 10.3892/or.2017.5460. Epub 2017 Feb 16.